Home / Providers / LillyDirect
Provider fact sheet · dataset v2026.08.14-4 · last touched 2026-08-14
LillyDirect: GLP-1 programs, prices, and verification status (2026)
LillyDirect is a unverified entry in our universe. Eli Lilly's direct channel — the FDA-approved benchmark every compounded price should be judged against.
Programs and pricing, in plain sentences
tirzepatide (injection (brand vials)) — status: unverified. $349-499/mo by dose, self-pay; the only FDA-approved product in this dataset
Foundayo (orforglipron) (oral tablet (non-peptide)) is advertised at $149/month, with a true recurring cost we compute at $149–$349/month — status: reported. Key fields: no membership fee; no commitment required; price rises with dose; 12-month total $1,788–$4,188. Approved Apr 1 2026; self-pay $149 (0.8mg) to $349 (14.5/17.2mg); $25/mo eligible commercial; $50/mo Medicare Bridge.
Every figure above carries its status — operator claims come from the provider, reported from third parties we cite, verified only after our own checkout walk. Machine-readable version: providers.json.
Update — August 14, 2026: Aggregator staleness confirmed, in our favor: the April 2026 tirzepatide.us.com comparison still lists LillyDirect vials at $349–599 — and contradicts itself ($349–499 in its own tier summary) — versus the $299/399/449 in-window pricing from Lilly's December 1, 2025 investor announcement, which governs our record. When aggregators disagree with the manufacturer's primary source, the primary source wins; this is exactly the stale-data pattern our December correction was written to catch.
Verification status and open items
Current status: unverified, last touched 2026-08-14. Open verification items: dispensing pharmacy identity, state coverage map, cancellation terms. Source on file: tirzepatide.us.com. Corrections land within 48 hours via the public log — if your checkout contradicts this page, that report changes the dataset.
How LillyDirect fits the market
Eli Lilly's direct channel — the FDA-approved benchmark every compounded price should be judged against. Zepbound single-dose vials run $299 (2.5 mg), $399 (5 mg), and $449 (7.5–15 mg) after the December 2025 cut, with the 45-day refill window as the fine print; Foundayo, the approved daily pill, ships here at $149–349. Where it lands overall: the price ladder, the category winners, and the program finder all compute from the same dataset this page renders.
Advertising disclosure: outbound provider links may be commission-bearing; our partner relationship with NexLife is disclosed on the ownership page and never alters statuses or rankings.